Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Statins as immunosuppressive agents - Statins as a newly recognized type of immunomodulator
Autore:
Kobashigawa, JA;
Indirizzi:
Univ Calif Los Angeles, Div Cardiol, Med Ctr, Los Angeles, CA 90095 USA Univ Calif Los Angeles Los Angeles CA USA 90095 Los Angeles, CA 90095 USA
Titolo Testata:
LIVER TRANSPLANTATION
fascicolo: 6, volume: 7, anno: 2001,
pagine: 559 - 561
SICI:
1527-6465(200106)7:6<559:SAIA-S>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
AVERAGE CHOLESTEROL LEVELS; CARDIAC TRANSPLANTATION; MYOCARDIAL-INFARCTION; CHRONIC REJECTION; CORONARY EVENTS; PRAVASTATIN; DISEASE; ALLOGRAFTS; IMMUNE; RISK;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Kobashigawa, JA Univ Calif Los Angeles, Div Cardiol, Med Ctr, 100 UCLA MedPlaza 630, Los Angeles, CA 90095 USA Univ Calif Los Angeles 100 UCLA Med Plaza 630 Los Angeles CA USA 90095
Citazione:
J.A. Kobashigawa, "Statins as immunosuppressive agents - Statins as a newly recognized type of immunomodulator", LIVER TRANS, 7(6), 2001, pp. 559-561

Abstract

Background Coronary artery disease in the transplanted heart, also known as cardiac allograft vasculopathy, is one of the major causes of mortality late after heart transplantation. This accelerated form of atherosclerosis also affects the donor organs of other transplant recipients including that of liver, kidney and lung. There are multiple immune and non-immune risk factors associated with this disease process, one of which is hyperlipidemia. Use of lipid lowering agents, specifically HMG-CoA reductase inhibitors (statins) was initially reported to have outcomes benefit and possibly immunosuppressive effects in a single center study of heart transplant recipients. Other subsequent studies have supported this beneficial effect. Method and Results: In a recent paper by Kwak and colleagues, the specific mechanismfor this immunosuppressive effect has been elucidated through the use of experiments monitoring cell surface expression assayed by fluorescence-activated cell sorting and by immunofluorescence as well as mRNA levels of majorhistocompatibility complex class II (MHC-II). They report that statins repress induction of MHC-II by interferon-gamma and that this in turn represses activation of T-lymphocytes and other cell types including primary human smooth. muscle cells and fibroblasts, as well as in established cell. linessuch as ThP1, melanomas, and HeLa cells. Conclusion: In addition to previous clinical and laboratory publications this work by Kwak and colleagues has provided a firm scientific rationale to support the use of statins as adjunct immunosuppressive agents in organ transplantation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 02:33:08